These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 22471363

  • 1. The effect of poloxamer 407 on the functional properties of HDL in mice.
    Yasuda T, Johnston TP, Shinohara M, Inoue M, Ishida T.
    J Pharm Pharmacol; 2012 May; 64(5):677-87. PubMed ID: 22471363
    [Abstract] [Full Text] [Related]

  • 2. Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1 and E-selectin, in C57BL/6 mice.
    Johnston TP.
    J Pharm Pharmacol; 2009 Dec; 61(12):1681-8. PubMed ID: 19958592
    [Abstract] [Full Text] [Related]

  • 3. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H, Pahl MV, Elahimehr R, Vaziri ND.
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [Abstract] [Full Text] [Related]

  • 4. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
    Kujiraoka T, Hattori H, Ito M, Nanjee MN, Ishihara M, Nagano M, Iwasaki T, Cooke CJ, Olszewski WL, Stepanova IP, Egashira T, Miller NE.
    Atherosclerosis; 2004 Sep; 176(1):57-62. PubMed ID: 15306175
    [Abstract] [Full Text] [Related]

  • 5. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.
    Circ Res; 2004 Oct 15; 95(8):789-97. PubMed ID: 15388641
    [Abstract] [Full Text] [Related]

  • 6. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect.
    Johnston TP, Zhou X.
    J Cardiovasc Pharmacol; 2007 Apr 15; 49(4):246-52. PubMed ID: 17438410
    [Abstract] [Full Text] [Related]

  • 7. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
    Brites FD, Verona J, Schreier LE, Fruchart JC, Castro GR, Wikinski RL.
    Arch Med Res; 2004 Apr 15; 35(3):235-40. PubMed ID: 15163466
    [Abstract] [Full Text] [Related]

  • 8. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.
    Nephrol Dial Transplant; 2006 May 15; 21(5):1270-7. PubMed ID: 16421163
    [Abstract] [Full Text] [Related]

  • 9. HDL capacity to inhibit LDL oxidation in well-trained triathletes.
    Brites F, Zago V, Verona J, Muzzio ML, Wikinski R, Schreier L.
    Life Sci; 2006 May 22; 78(26):3074-81. PubMed ID: 16488445
    [Abstract] [Full Text] [Related]

  • 10. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.
    Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB.
    Clin Sci (Lond); 2004 Apr 22; 106(4):421-32. PubMed ID: 14717654
    [Abstract] [Full Text] [Related]

  • 11. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF.
    Ann Rheum Dis; 2009 Jun 22; 68(6):868-72. PubMed ID: 18635596
    [Abstract] [Full Text] [Related]

  • 12. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
    De Geest B, Stengel D, Landeloos M, Lox M, Le Gat L, Collen D, Holvoet P, Ninio E.
    Arterioscler Thromb Vasc Biol; 2000 Oct 22; 20(10):E68-75. PubMed ID: 11031226
    [Abstract] [Full Text] [Related]

  • 13. Methionine-induced hyperhomocysteinemia impairs the antioxidant ability of high-density lipoproteins without reducing in vivo macrophage-specific reverse cholesterol transport.
    Julve J, Escolà-Gil JC, Rodríguez-Millán E, Martín-Campos JM, Jauhiainen M, Quesada H, Rentería-Obregón IM, Osada J, Sánchez-Quesada JL, Blanco-Vaca F.
    Mol Nutr Food Res; 2013 Oct 22; 57(10):1814-24. PubMed ID: 23754667
    [Abstract] [Full Text] [Related]

  • 14. Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS.
    Fan P, Liu H, Wang Y, Zhang F, Bai H.
    Reprod Biomed Online; 2012 Feb 22; 24(2):197-205. PubMed ID: 22197603
    [Abstract] [Full Text] [Related]

  • 15. The influence of repeated administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart.
    Korolenko TA, Tuzikov FV, Johnston TP, Tuzikova NA, Kisarova YA, Zhanaeva SY, Alexeenko TV, Zhukova NA, Brak IV, Spiridonov VK, Filjushina EE, Cherkanova MS, Monoszon AA.
    Can J Physiol Pharmacol; 2012 Nov 22; 90(11):1456-68. PubMed ID: 23181274
    [Abstract] [Full Text] [Related]

  • 16. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
    Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, Stuart WD, Rubin EM, Ng DS.
    J Lipid Res; 1999 Jul 22; 40(7):1276-83. PubMed ID: 10393212
    [Abstract] [Full Text] [Related]

  • 17. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
    Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN.
    J Clin Invest; 1998 Apr 15; 101(8):1581-90. PubMed ID: 9541487
    [Abstract] [Full Text] [Related]

  • 18. Circulating adhesion molecules in apoE-deficient mouse strains with different atherosclerosis susceptibility.
    Tian J, Pei H, James JC, Li Y, Matsumoto AH, Helm GA, Shi W.
    Biochem Biophys Res Commun; 2005 Apr 15; 329(3):1102-7. PubMed ID: 15752767
    [Abstract] [Full Text] [Related]

  • 19. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
    Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P.
    Circulation; 2003 Apr 01; 107(12):1640-6. PubMed ID: 12668499
    [Abstract] [Full Text] [Related]

  • 20. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
    Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, Witztum JL, Fallon JT, Fisher EA.
    Arterioscler Thromb Vasc Biol; 2004 Oct 01; 24(10):1904-9. PubMed ID: 15319266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.